Abstract
Background The functional status of lipoprotein particles contributes to atherogenesis. The tendency of plasma LDL particles to aggregate and the ability of HDL particles to induce and mediate reverse cholesterol transport associate with high and low risk for cardiovascular disease in adult patients, respectively. However, it is unknown whether children with familial hypercholesterolemia (FH) display lipoprotein function alterations.
Hypothesis We hypothesized that FH children had disrupted lipoprotein function.
Methods We analyzed LDL aggregation susceptibility and HDL-apoA-I exchange to apoA-I ratio (HAE/apoA-I ratio), and activity of four proteins that regulate lipoprotein metabolism (CETP, LCAT, PLTP and PON1) in plasma samples derived from children with FH (n = 47) and from healthy children (n = 56). Potential biological mechanisms behind any variation in lipoprotein functionalities were explored using an NMR-based metabolomics profiling approach.
Results LDL aggregation was higher and HAE/apoA-I ratio was lower in FH children than in healthy children. LDL aggregation associated positively with LDL-C and negatively with triglycerides, and HAE/apoA-I ratio associated negatively with LDL-C. Generally, the metabolomic profile for LDL aggregation was a mirror image of that for HAE/apoA-I ratio.
Conclusions FH children displayed increased atherogenicity of LDL and disrupted HDL function. These newly observed functional alterations in LDL and HDL may increase the risk for atherosclerotic cardiovascular disease in FH children.
Competing Interest Statement
Dr. Christensen has received research grants and/or personal fees from Mills DA, unrelated to the content of this manuscript. Drs. Ruuth, Kovanen and Oorni have applied for a patent on the LDL aggregation method; otherwise they have no other relevant financial relationships to disclose. Dr. Ulven has received research grants from Tine DA, Mills DA, and Olympic Seafood, none of which are related to the content of this manuscript. Dr. Retterstol reports personal fees from Amgen, Mills DA, The Norwegian Medical Association, The Norwegian Directorate of Health, Sanofi, Takeda, Chiesi, Bayer, MSD, and research grants from Oslo Economics and Mills outside the submitted work. Dr. Heier has received a research grant from the Norwegian Diabetes Association for analyses included in this manuscript. Dr. Holven has received research grants and/or personal fees from Tine DA, Mills DA, Olympic Seafood, Amgen, Sanofi, and Pronova, none of which are related to the content of this manuscript. The other authors have no relevant financial relationships to disclose.
Funding Statement
This work was funded by the University of Oslo (Oslo, Norway), the National Advisory Unit on FH at OUH (Oslo, Norway), the Throne-Holst Foundation for Nutrition Research (Oslo, Norway), the South-Eastern Regional Health Authority (Oslo, Norway), the Academy of Finland (#315568 and #332564 to KO), the Jane and Aatos Erkko Foundation (to MJ), the Finnish Foundation for Cardiovascular Research (to MJ and KO), the Aarne Koskelo Foundation (to KO), and the Novo Nordisk Foundation (to KO). Wihuri Research Institute is maintained by the Jenny and Antti Wihuri Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Regional Committee for Research Ethics in South East Norway approved the study, and the study protocol was in accordance with the declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared last authorship
Disclaimers: None.
Data Availability
Summary statistics are available in Supplementary Material, but individual level raw data will not be made available.
Abbreviations
- apoA-I
- apolipoprotein A-I
- apoB
- apolipoprotein B
- ASCVD
- atherosclerotic cardiovascular disease
- BMI
- body mass index
- BCAAs
- branched-chain amino acids
- CETP
- cholesteryl ester transfer protein
- DHA
- docosahexaenoic acid;
- FA
- fatty acids
- FH
- familial hypercholesterolemia
- HAE
- HDL-apoA-I exchange
- HDL
- high-density lipoprotein
- LA
- linoleic acid
- LCAT
- lecithin–cholesterol acyltransferase
- LDL
- low-density lipoprotein
- LDL aggr (PP)
- LDL aggregation (per particle)
- LDL aggr (TL)
- LDL aggregation (total load)
- LDLR
- LDL receptor
- MUFA
- monounsaturated fatty acids
- n3
- omega-3 fatty acids
- n6
- omega-6 fatty acids
- PC
- phosphatidylcholine
- PLTP
- phospholipid transfer protein
- PON1
- paraoxonase-1
- PUFA
- polyunsaturated fatty acids
- RCT
- reverse cholesterol transport
- SFA
- saturated fatty acids
- SM
- sphingomyelins
- VLDL
- very low-density lipoprotein
